KalVista Pharmaceuticals, Inc. - Common Stock (KALV)

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of

KalVista stock rises 7.4% on strong EKTERLY launch, despite Q1 revenue miss and wider EPS loss. Early HAE treatment adoption exceeds expectations.

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous or subcutaneous administration.

The FDA signed off on KalVista Pharmaceuticals' emergency treatment for swelling attacks associated with a rare disease.

KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US.

The company is working on the first new on-demand treatment for hereditary angioedema in 11 years.

KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the fourth quarter of 2024.